NASDAQ:NXTC - NextCure Stock Price, Forecast & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NXTC stock has decreased by 4.2% and is now trading at $36.61. View which stocks have been mosted impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Monday, June 8th 2020. View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.02. The company earned $1.58 million during the quarter, compared to analysts' expectations of $1.50 million. NextCure had a negative return on equity of 21.84% and a negative net margin of 531.54%. View NextCure's earnings history.

8 brokers have issued 12-month price targets for NextCure's stock. Their forecasts range from $44.00 to $87.00. On average, they expect NextCure's share price to reach $66.50 in the next year. This suggests a possible upside of 81.6% from the stock's current price. View analysts' price targets for NextCure.

Media coverage about NXTC stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. NextCure earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNextCure.

NextCure saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,296,200 shares, an increase of 11.7% from the February 27th total of 1,160,000 shares. Based on an average daily trading volume, of 224,800 shares, the short-interest ratio is currently 5.8 days. Currently, 8.1% of the shares of the company are sold short. View NextCure's Current Options Chain.

Some companies that are related to NextCure include United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN), PTC Therapeutics (PTCT), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB) and Agios Pharmaceuticals (AGIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Honeywell International (HON), Amgen (AMGN), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), CVS Health (CVS), AT&T (T), Verizon Communications (VZ), NVIDIA (NVDA), Home Depot (HD) and Altria Group (MO).

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure's stock is owned by many different retail and institutional investors. Top institutional investors include Sofinnova Investments Inc. (11.74%), Canaan Partners X LLC (9.91%), Lord Abbett & CO. LLC (6.34%), Alliancebernstein L.P. (4.67%), ArrowMark Colorado Holdings LLC (3.35%) and State Street Corp (1.83%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View institutional ownership trends for NextCure.

NXTC stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, EAM Global Investors LLC, EAM Investors LLC, UBS Group AG, J. Goldman & Co LP, and Bamco Inc. NY. View insider buying and selling activity for NextCure.

NXTC stock was purchased by a variety of institutional investors in the last quarter, including Canaan Partners X LLC, Lord Abbett & CO. LLC, ArrowMark Colorado Holdings LLC, Alliancebernstein L.P., State Street Corp, Marshall Wace North America L.P., Sofinnova Investments Inc., and FMR LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan. View insider buying and selling activity for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $36.61.

NextCure has a market capitalization of $1.01 billion and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.  View additional information about NextCure.

The official website for NextCure is http://www.nextcure.com/.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]